<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00394654</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP138</org_study_id>
    <nct_id>NCT00394654</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma</brief_title>
  <official_title>A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy of MEDI-528, a Humanized Anti-Interleukin-9 Monoclonal Antibody, on Late Asthmatic Response Induced By Allergen Inhalation In Adults With Atopic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2a, randomized multicenter study to evaluate the efficacy of MEDI-528 on LAR
      in adult patients with atopic asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study (MI-CP138) is a Phase 2a, randomized, double-blind, placebo-controlled,
      multicenter study to evaluate the efficacy of MEDI-528 on LAR in adult patients with atopic
      asthma. Approximately three investigative sites in Canada will participate in this study,
      with up to 40 evaluable patients randomized in a 1:1 ratio to receive MEDI-528 (9.0 mg/kg) or
      placebo as a single IV infusion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of MEDI-528 on Late Asthmatic Response (LAR) After Inhaled Allergen Challenge at Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline (percent reduction) in mean maximum decline of forced expiratory volume in one second (FEV1) during LAR at 3 to 7 hours after an inhaled allergen challenge.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Change from baseline (percent reduction) in mean maximum decline of FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 56</measure>
    <time_frame>Day 56</time_frame>
    <description>Change from baseline (percent reduction) in mean maximum decline of FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline (percent reduction) in mean maximum decline of area under the concentration-time curve (AUC) of the participants FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Change from baseline (percent reduction) in mean maximum decline of AUC of the participants FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 56</measure>
    <time_frame>Day 56</time_frame>
    <description>Change from baseline (percent reduction) in mean maximum decline of AUC of the participants FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Days 0 - 126</time_frame>
    <description>Number of participants experiencing adverse events (includes both adverse events and serious adverse events)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events</measure>
    <time_frame>Days 0 - 126</time_frame>
    <description>Number of participants experiencing serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Anti-drug Antibodies (ADA) to MEDI-528</measure>
    <time_frame>Days 0, 27, 55, 84, and 126</time_frame>
    <description>Number of participants with ADA to MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Observed Maximum Serum Concentration (Tmax)</measure>
    <time_frame>Days 0, 6, 7, 27, 55, 84, and 126</time_frame>
    <description>Tmax of MEDI-528 in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Observed Maximum Sputum Concentration (Tmax)</measure>
    <time_frame>Days -21 to -7, 7, 28, and 56</time_frame>
    <description>Tmax of MEDI-528 in sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Observed Maximum Nasal Lavage Concentration (Tmax)</measure>
    <time_frame>Days -6 to -1, 8, 29, and 57</time_frame>
    <description>Tmax of MEDI-528 in nasal lavage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Serum Concentration (Cmax)</measure>
    <time_frame>Days 0, 6, 7, 27, 55, 84, and 126</time_frame>
    <description>Cmax of MEDI-528 in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Sputum Concentration (Cmax)</measure>
    <time_frame>Days -21 to -7, 7, 28, and 56</time_frame>
    <description>Cmax of MEDI-528 in sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Nasal Lavage Concentration (Cmax)</measure>
    <time_frame>Days -6 to -1, 8, 29, and 57</time_frame>
    <description>Cmax of MEDI-528 in nasal lavage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]</measure>
    <time_frame>Days 0, 6, 7, 27, 55, 84, and 126</time_frame>
    <description>AUC(0-t) of MEDI-528 in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]</measure>
    <time_frame>Days -21 to -7, 7, 28, and 56</time_frame>
    <description>AUC(0-t) of MEDI-528 in sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]</measure>
    <time_frame>Days -6 to -1, 8, 29, and 57</time_frame>
    <description>AUC(0-t) of MEDI-528 in nasal lavage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]</measure>
    <time_frame>Days 0, 6, 7, 27, 55, 84, and 126</time_frame>
    <description>AUC(0-infinity) of MEDI-528 in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]</measure>
    <time_frame>Days -21 to -7, 7, 28, and 56</time_frame>
    <description>AUC(0-infinity) of MEDI-528 in sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]</measure>
    <time_frame>Days -6 to -1, 8, 29, and 57</time_frame>
    <description>AUC(0-infinity) of MEDI-528 in nasal lavage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]</measure>
    <time_frame>Days 0, 6, 7, 27, 55, 84, and 126</time_frame>
    <description>AUC(ext) of MEDI-528 in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]</measure>
    <time_frame>Days -21 to -7, 7, 28, and 56</time_frame>
    <description>AUC(ext) of MEDI-528 in sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]</measure>
    <time_frame>Days -6 to -1, 8, 29, and 57</time_frame>
    <description>AUC(ext) of MEDI-528 in nasal lavage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Half-Life (T1/2)</measure>
    <time_frame>Days 0, 6, 7, 27, 55, 84, and 126</time_frame>
    <description>T1/2 of MEDI-528 in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Half-Life (T1/2)</measure>
    <time_frame>Days -21 to -7, 7, 28, and 56</time_frame>
    <description>T1/2 of MEDI-528 in sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Half-Life (T1/2)</measure>
    <time_frame>Days -6 to -1, 8, 29, and 57</time_frame>
    <description>T1/2 of MEDI-528 in nasal lavage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Clearance (CL)</measure>
    <time_frame>Days 0, 6, 7, 27, 55, 84, and 126</time_frame>
    <description>CL of MEDI-528 in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Volume of Distribution (Vz)</measure>
    <time_frame>Days 0, 6, 7, 27, 55, 84, and 126</time_frame>
    <description>Vz of MEDI-528 in serum</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>MEDI528 9 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered as a single intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-528 9 mg/kg</intervention_name>
    <description>MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion</description>
    <arm_group_label>MEDI528 9 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered as a single intravenous infusion</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adults, age 18 through 65 years of age at the time of screening;

          -  Written informed consent obtained from the patient prior to receipt of any study
             medication or beginning study procedures;

          -  Previously documented diagnosis of asthma of &gt; 1 year duration, based on episodic
             symptoms of airflow obstruction, at least partial reversibility of airflow
             obstruction, with alternative diagnoses (e.g., chronic obstructive pulmonary disease)
             ruled out;

          -  AHR in the methacholine challenge test with a PC20 (provoking concentration of
             methacholine to cause a 20% fall in FEV1) ≤ 16 mg/mL (Crapo, 2000);

          -  Have dual response of EAR, defined as a decrease in FEV1 ≥ 20% at 0 to 3 hours after
             inhalation, and LAR, defined as a decrease in FEV1 ≥ 15% 3 to 7 hours after
             inhalation, to inhaled allergen;

          -  Asthma symptoms are adequately controlled on short-acting β2 agonists (e.g.,
             albuterol) alone;

          -  Have had no significant changes in regular asthma medications and no acute asthma
             exacerbations requiring corticosteroid rescue, hospitalization, or emergency
             department visits for at least 4 weeks prior to screening and up through the time of
             the first dose of study drug on Study Day 0.

          -  Sexually active women, unless surgically sterile or at least 1 year post-menopausal,
             must have used an effective method of avoiding pregnancy (including oral or implanted
             contraceptives, intrauterine device, female condom, diaphragm with spermicide,
             cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual
             partner) for 21 days prior to the first dose of study drug on Study Day 0, and must
             agree to continue using such precautions through Study Day 126. Cessation of birth
             control after this point should be discussed with a responsible physician. Sexually
             active men, unless surgically sterile, must likewise use an effective method of birth
             control (condom) and must agree to continue using such precautions through Study Day
             126;

          -  Able to complete the follow-up period through Study Day 126, as required by the
             protocol.

          -  Willing to forego other forms of experimental treatment and study procedures during
             the study; and

          -  Able to provide spirometric readings that meet American Thoracic Society (ATS)
             standards (ATS, 1995).

        Exclusion Criteria:

          -  Receipt of MEDI-528 in any previous clinical study;

          -  History of allergy or adverse reactions to any component of the MEDI-528 formulation;

          -  Lung disease other than allergic asthma (e.g. chronic bronchitis);

          -  Current use of any systemic or inhaled immunosuppressive drugs, including systemic and
             inhaled corticosteroids (topical corticosteroids are permitted), long-acting β2
             agonists, leukotriene antagonists, cromolyn sodium, nedocromil sodium, theophylline or
             any inhaled or systemic medication for asthma other than short-acting β2 agonists, for
             at least 4 weeks prior to study drug administration on Study Day 0.

          -  Current use of any β-adrenergic antagonist (e.g. propranolol).

          -  Any disease or illness, other than asthma, that may require the use of systemic
             corticosteroids during the study period.

          -  Acute illnesses or evidence of clinically significant active infection, such as fever
             ³ 38.0°C (100.5°F) at screening and through the time of the study drug administration
             on Study Day 0;

          -  Current allergy-vaccination therapy (i.e., desensitization immunotherapy) with less
             than 3 months of stable maintenance doses prior to the baseline allergen inhalation
             challenge;

          -  Receipt of any investigational drug therapy within 30 days or any biologic(s) within 5
             half-lives of the agent prior to the first dose of study drug through Study Day 150;

          -  Receipt of any therapy with a leukocyte-depleting agent unless recovery in white cell
             count has been documented before screening;

          -  Pregnancy (sexually active females must have a negative serum pregnancy test at
             screening and a negative urine pregnancy test prior to study drug administration on
             Study Day 0);

          -  Is a nursing mother at the time of study enrollment;

          -  Evidence of infection with hepatitis B or C virus, or HIV-1 or HIV-2, or active
             infection with hepatitis A;

          -  History of significant systemic disease (e.g., cancer; infection; coronary artery
             disease or other cardiovascular disease; or hematological, renal, hepatic,
             endocrinologic, neurologic, rheumatologic, or gastrointestinal disease);

          -  History of cancer other than nonmelanoma skin cancer or cervical carcinoma-in-situ
             that have been treated successfully with curative therapy;

          -  History of primary immunodeficiency;

          -  History of pancreatitis;

          -  History of use of tobacco products within 2 years of baseline or history of smoking &gt;=
             10 pack-years;

          -  Elective surgery planned from the time of screening through Study Day 126;

          -  Clinically significant abnormalities (other than asthma) upon physical examination
             prior to study drug administration on Study Day 0;

          -  Clinically significant abnormality, as determined by the investigator, on 12-lead ECG
             or chest radiograph at the time of screening;

          -  At the time of screening, any of the following abnormalities: aspartate transaminase
             (AST), alanine transaminase (ALT), or amylase &gt; 1.5 × above the upper limits of normal
             (ULN); or serum creatinine &gt; 1.3 × ULN; or any other abnormal laboratory values in the
             screening panel that, in the opinion of the principal investigator (PI), are judged to
             be clinically significant; or

          -  Evidence of any systemic disease or respiratory disease (other than asthma), any
             finding upon physical examination or history of any disease that, in the opinion of
             the PI or medical monitor, may compromise the safety of the patient in the study or
             confound the analysis of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nestor Molfino, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2006</study_first_submitted>
  <study_first_submitted_qc>October 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2006</study_first_posted>
  <results_first_submitted>October 18, 2013</results_first_submitted>
  <results_first_submitted_qc>October 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 11, 2013</results_first_posted>
  <last_update_submitted>October 18, 2013</last_update_submitted>
  <last_update_submitted_qc>October 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Thirty patients were entered into the study between 16Oct2006 and 15Aug2007 at 2 sites in Canada.</recruitment_details>
      <pre_assignment_details>Treatment assignments were determined using a block randomization procedure with a 1:1 ratio through an interactive Web response system (IWRS). Patients who were randomized into the study but did not complete the second allergen challenge on Day 7 were replaced, unless the patient withdrew for safety reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PLACEBO</title>
        </group>
        <group group_id="P2">
          <title>MEDI528 9 mg/kg</title>
          <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>PARTICIPANT LEFT STDUY REGION</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PLACEBO</title>
        </group>
        <group group_id="B2">
          <title>MEDI528 9 mg/kg</title>
          <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.5" spread="9.6"/>
                    <measurement group_id="B2" value="26.5" spread="7.8"/>
                    <measurement group_id="B3" value="28.5" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of MEDI-528 on Late Asthmatic Response (LAR) After Inhaled Allergen Challenge at Day 7</title>
        <description>Change from baseline (percent reduction) in mean maximum decline of forced expiratory volume in one second (FEV1) during LAR at 3 to 7 hours after an inhaled allergen challenge.</description>
        <time_frame>Day 7</time_frame>
        <population>All participants who were randomized into the study and completed the second allergen challenge on Day 7.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of MEDI-528 on Late Asthmatic Response (LAR) After Inhaled Allergen Challenge at Day 7</title>
          <description>Change from baseline (percent reduction) in mean maximum decline of forced expiratory volume in one second (FEV1) during LAR at 3 to 7 hours after an inhaled allergen challenge.</description>
          <population>All participants who were randomized into the study and completed the second allergen challenge on Day 7.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.26" spread="69.288"/>
                    <measurement group_id="O2" value="-16.21" spread="61.788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.168</p_value>
            <method>Univariate 2-sample t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 28</title>
        <description>Change from baseline (percent reduction) in mean maximum decline of FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.</description>
        <time_frame>Day 28</time_frame>
        <population>All participants who were randomized into the study and completed the second allergen challenge on Day 7.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 28</title>
          <description>Change from baseline (percent reduction) in mean maximum decline of FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.</description>
          <population>All participants who were randomized into the study and completed the second allergen challenge on Day 7.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.93" spread="46.646"/>
                    <measurement group_id="O2" value="-16.95" spread="123.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.254</p_value>
            <method>Univariate 2-sample t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 56</title>
        <description>Change from baseline (percent reduction) in mean maximum decline of FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.</description>
        <time_frame>Day 56</time_frame>
        <population>All participants who were randomized into the study and completed the second allergen challenge on Day 7.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 56</title>
          <description>Change from baseline (percent reduction) in mean maximum decline of FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.</description>
          <population>All participants who were randomized into the study and completed the second allergen challenge on Day 7.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.36" spread="45.123"/>
                    <measurement group_id="O2" value="31.85" spread="53.709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.677</p_value>
            <method>Univariate 2-sample t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 7</title>
        <description>Change from baseline (percent reduction) in mean maximum decline of area under the concentration-time curve (AUC) of the participants FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.</description>
        <time_frame>Day 7</time_frame>
        <population>All participants who were randomized into the study and completed the second allergen challenge on Day 7.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 7</title>
          <description>Change from baseline (percent reduction) in mean maximum decline of area under the concentration-time curve (AUC) of the participants FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.</description>
          <population>All participants who were randomized into the study and completed the second allergen challenge on Day 7.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.86" spread="94.34"/>
                    <measurement group_id="O2" value="-14.47" spread="82.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.318</p_value>
            <method>Univariate 2-sample t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 28</title>
        <description>Change from baseline (percent reduction) in mean maximum decline of AUC of the participants FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.</description>
        <time_frame>Day 28</time_frame>
        <population>All participants who were randomized into the study and completed the second allergen challenge on Day 7.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 28</title>
          <description>Change from baseline (percent reduction) in mean maximum decline of AUC of the participants FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.</description>
          <population>All participants who were randomized into the study and completed the second allergen challenge on Day 7.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="133.75"/>
                    <measurement group_id="O2" value="-13.09" spread="175.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.798</p_value>
            <method>Univariate 2-sample t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 56</title>
        <description>Change from baseline (percent reduction) in mean maximum decline of AUC of the participants FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.</description>
        <time_frame>Day 56</time_frame>
        <population>All participants who were randomized into the study and completed the second allergen challenge on Day 7.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 56</title>
          <description>Change from baseline (percent reduction) in mean maximum decline of AUC of the participants FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.</description>
          <population>All participants who were randomized into the study and completed the second allergen challenge on Day 7.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.75" spread="65.49"/>
                    <measurement group_id="O2" value="51.91" spread="98.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.766</p_value>
            <method>Univariate 2-sample t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events</title>
        <description>Number of participants experiencing adverse events (includes both adverse events and serious adverse events)</description>
        <time_frame>Days 0 - 126</time_frame>
        <population>All subjects who received at least one dose of investigational product (MEDI-528 or placebo)</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <description>Number of participants experiencing adverse events (includes both adverse events and serious adverse events)</description>
          <population>All subjects who received at least one dose of investigational product (MEDI-528 or placebo)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Serious Adverse Events</title>
        <description>Number of participants experiencing serious adverse events</description>
        <time_frame>Days 0 - 126</time_frame>
        <population>All subjects who received at least one dose of investigational product (MEDI-528 or placebo)</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events</title>
          <description>Number of participants experiencing serious adverse events</description>
          <population>All subjects who received at least one dose of investigational product (MEDI-528 or placebo)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Anti-drug Antibodies (ADA) to MEDI-528</title>
        <description>Number of participants with ADA to MEDI-528</description>
        <time_frame>Days 0, 27, 55, 84, and 126</time_frame>
        <population>All subjects who received at least one dose of investigational product (MEDI-528 or placebo)</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Anti-drug Antibodies (ADA) to MEDI-528</title>
          <description>Number of participants with ADA to MEDI-528</description>
          <population>All subjects who received at least one dose of investigational product (MEDI-528 or placebo)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Observed Maximum Serum Concentration (Tmax)</title>
        <description>Tmax of MEDI-528 in serum</description>
        <time_frame>Days 0, 6, 7, 27, 55, 84, and 126</time_frame>
        <population>All participants who were randomized and received any MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Observed Maximum Serum Concentration (Tmax)</title>
          <description>Tmax of MEDI-528 in serum</description>
          <population>All participants who were randomized and received any MEDI-528</population>
          <units>Day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.028" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Observed Maximum Sputum Concentration (Tmax)</title>
        <description>Tmax of MEDI-528 in sputum</description>
        <time_frame>Days -21 to -7, 7, 28, and 56</time_frame>
        <population>All participants who were randomized and received any MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Observed Maximum Sputum Concentration (Tmax)</title>
          <description>Tmax of MEDI-528 in sputum</description>
          <population>All participants who were randomized and received any MEDI-528</population>
          <units>Day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="9.276" spread="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Observed Maximum Nasal Lavage Concentration (Tmax)</title>
        <description>Tmax of MEDI-528 in nasal lavage</description>
        <time_frame>Days -6 to -1, 8, 29, and 57</time_frame>
        <population>All participants who were randomized and received any MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Observed Maximum Nasal Lavage Concentration (Tmax)</title>
          <description>Tmax of MEDI-528 in nasal lavage</description>
          <population>All participants who were randomized and received any MEDI-528</population>
          <units>Day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="10.319" spread="169.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Maximum Serum Concentration (Cmax)</title>
        <description>Cmax of MEDI-528 in serum</description>
        <time_frame>Days 0, 6, 7, 27, 55, 84, and 126</time_frame>
        <population>All participants who were randomized and received any MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Maximum Serum Concentration (Cmax)</title>
          <description>Cmax of MEDI-528 in serum</description>
          <population>All participants who were randomized and received any MEDI-528</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="229.672" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Maximum Sputum Concentration (Cmax)</title>
        <description>Cmax of MEDI-528 in sputum</description>
        <time_frame>Days -21 to -7, 7, 28, and 56</time_frame>
        <population>All participants who were randomized and received any MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Maximum Sputum Concentration (Cmax)</title>
          <description>Cmax of MEDI-528 in sputum</description>
          <population>All participants who were randomized and received any MEDI-528</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="71.843" spread="78.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Maximum Nasal Lavage Concentration (Cmax)</title>
        <description>Cmax of MEDI-528 in nasal lavage</description>
        <time_frame>Days -6 to -1, 8, 29, and 57</time_frame>
        <population>All participants who were randomized and received any MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Maximum Nasal Lavage Concentration (Cmax)</title>
          <description>Cmax of MEDI-528 in nasal lavage</description>
          <population>All participants who were randomized and received any MEDI-528</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="79.406" spread="136.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]</title>
        <description>AUC(0-t) of MEDI-528 in serum</description>
        <time_frame>Days 0, 6, 7, 27, 55, 84, and 126</time_frame>
        <population>All participants who were randomized and received any MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]</title>
          <description>AUC(0-t) of MEDI-528 in serum</description>
          <population>All participants who were randomized and received any MEDI-528</population>
          <units>Microgram times day per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5744.821" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]</title>
        <description>AUC(0-t) of MEDI-528 in sputum</description>
        <time_frame>Days -21 to -7, 7, 28, and 56</time_frame>
        <population>All participants who were randomized and received any MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]</title>
          <description>AUC(0-t) of MEDI-528 in sputum</description>
          <population>All participants who were randomized and received any MEDI-528</population>
          <units>Nanogram times day per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2382.123" spread="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]</title>
        <description>AUC(0-t) of MEDI-528 in nasal lavage</description>
        <time_frame>Days -6 to -1, 8, 29, and 57</time_frame>
        <population>All participants who were randomized and received any MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]</title>
          <description>AUC(0-t) of MEDI-528 in nasal lavage</description>
          <population>All participants who were randomized and received any MEDI-528</population>
          <units>Nanogram times day per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1332.408" spread="147.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]</title>
        <description>AUC(0-infinity) of MEDI-528 in serum</description>
        <time_frame>Days 0, 6, 7, 27, 55, 84, and 126</time_frame>
        <population>All participants who were randomized and received any MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]</title>
          <description>AUC(0-infinity) of MEDI-528 in serum</description>
          <population>All participants who were randomized and received any MEDI-528</population>
          <units>Microgram times day per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="6224.272" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]</title>
        <description>AUC(0-infinity) of MEDI-528 in sputum</description>
        <time_frame>Days -21 to -7, 7, 28, and 56</time_frame>
        <population>All participants who were randomized, received any MEDI-528, and had sputum samples obtained</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]</title>
          <description>AUC(0-infinity) of MEDI-528 in sputum</description>
          <population>All participants who were randomized, received any MEDI-528, and had sputum samples obtained</population>
          <units>Nanogram times day per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4136.234" spread="61.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]</title>
        <description>AUC(0-infinity) of MEDI-528 in nasal lavage</description>
        <time_frame>Days -6 to -1, 8, 29, and 57</time_frame>
        <population>All participants who were randomized, received any MEDI-528, and had nasal lavage samples obtained</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]</title>
          <description>AUC(0-infinity) of MEDI-528 in nasal lavage</description>
          <population>All participants who were randomized, received any MEDI-528, and had nasal lavage samples obtained</population>
          <units>Nanogram times day per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="6047.098" spread="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]</title>
        <description>AUC(ext) of MEDI-528 in serum</description>
        <time_frame>Days 0, 6, 7, 27, 55, 84, and 126</time_frame>
        <population>All participants who were randomized and received any MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]</title>
          <description>AUC(ext) of MEDI-528 in serum</description>
          <population>All participants who were randomized and received any MEDI-528</population>
          <units>Percent</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="6.441" spread="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]</title>
        <description>AUC(ext) of MEDI-528 in sputum</description>
        <time_frame>Days -21 to -7, 7, 28, and 56</time_frame>
        <population>All participants who were randomized, received any MEDI-528, and had sputum samples obtained</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]</title>
          <description>AUC(ext) of MEDI-528 in sputum</description>
          <population>All participants who were randomized, received any MEDI-528, and had sputum samples obtained</population>
          <units>Percent</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="25.919" spread="81.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]</title>
        <description>AUC(ext) of MEDI-528 in nasal lavage</description>
        <time_frame>Days -6 to -1, 8, 29, and 57</time_frame>
        <population>All participants who were randomized, received any MEDI-528, and had nasal lavage samples obtained</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]</title>
          <description>AUC(ext) of MEDI-528 in nasal lavage</description>
          <population>All participants who were randomized, received any MEDI-528, and had nasal lavage samples obtained</population>
          <units>Percent</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="18.848" spread="178.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Phase Half-Life (T1/2)</title>
        <description>T1/2 of MEDI-528 in serum</description>
        <time_frame>Days 0, 6, 7, 27, 55, 84, and 126</time_frame>
        <population>All participants who were randomized and received any MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Half-Life (T1/2)</title>
          <description>T1/2 of MEDI-528 in serum</description>
          <population>All participants who were randomized and received any MEDI-528</population>
          <units>Day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="34.316" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Phase Half-Life (T1/2)</title>
        <description>T1/2 of MEDI-528 in sputum</description>
        <time_frame>Days -21 to -7, 7, 28, and 56</time_frame>
        <population>All participants who were randomized, received any MEDI-528, and had sputum samples obtained</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Half-Life (T1/2)</title>
          <description>T1/2 of MEDI-528 in sputum</description>
          <population>All participants who were randomized, received any MEDI-528, and had sputum samples obtained</population>
          <units>Day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="31.933" spread="83.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Phase Half-Life (T1/2)</title>
        <description>T1/2 of MEDI-528 in nasal lavage</description>
        <time_frame>Days -6 to -1, 8, 29, and 57</time_frame>
        <population>All participants who were randomized, received any MEDI-528, and had nasal lavage samples obtained</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Half-Life (T1/2)</title>
          <description>T1/2 of MEDI-528 in nasal lavage</description>
          <population>All participants who were randomized, received any MEDI-528, and had nasal lavage samples obtained</population>
          <units>Day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="25.584" spread="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Clearance (CL)</title>
        <description>CL of MEDI-528 in serum</description>
        <time_frame>Days 0, 6, 7, 27, 55, 84, and 126</time_frame>
        <population>All participants who were randomized and received any MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Clearance (CL)</title>
          <description>CL of MEDI-528 in serum</description>
          <population>All participants who were randomized and received any MEDI-528</population>
          <units>Liter per day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.101" spread="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Phase Volume of Distribution (Vz)</title>
        <description>Vz of MEDI-528 in serum</description>
        <time_frame>Days 0, 6, 7, 27, 55, 84, and 126</time_frame>
        <population>All participants who were randomized and received any MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous (IV) infusion</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Volume of Distribution (Vz)</title>
          <description>Vz of MEDI-528 in serum</description>
          <population>All participants who were randomized and received any MEDI-528</population>
          <units>Liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5.025" spread="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PLACEBO</title>
        </group>
        <group group_id="E2">
          <title>MEDI528 9 mg/kg</title>
          <description>MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Chlamydial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Don Raible, MD</name_or_title>
      <organization>MedImmune</organization>
      <phone>301-398-0000</phone>
      <email>raibleD@medimmune.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

